An investment research firm wanted to prove AI could revolutionize drug development. So they teamed up with Anthropic to see whether an unreleased version of Claude could make scorpion antivenom. It couldn't. It came up with some promising starting points, but nothing close to an actual drug, experts tell The Verge. Citrini Research, the firm […]
This article has been indexed from AI | The Verge
Read the original article: